Drug value assessments generally fail to account for the complexities of health care systems and thus can misinform price negotiations and lead to overly restrictive access policies. Our [new article … Read More
Mara Palm joins NEWDIGS
We are pleased to announce that Marisha (Mara) Palm, MSC, PhD has joined our research team at the Center for Biomedical System Design. Mara has played a leadership role in our work … Read More
NEWDIGS leaders named to Illinois SCD Advisory Council
Our Strategic Director Mark Trusheim was appointed by Illinois Governor Pritzker to the Advisory Council on Financing and Access to Sickle Cell Disease Treatment and Other High-Cost Drugs & Treatment. Rena … Read More
ISPOR 2024 panel recap: Will the Pediatric Rare Disease Pipeline Create a Financial Tsunami? Implications of a Monte Carlo Projection
Atlanta, GA – On Monday, May 6, NEWDIGS community members presented a panel discussion at the annual ISPOR meeting, “Will the Pediatric Rare Disease Pipeline Create a Financial Tsunami? Implications of … Read More
BioCentury OpEd: Biomedical Innovation Requires Health System Innovation
New guest commentary in BioCentury by Gigi Hirsch & Jane Barlow seeds a series of discussions now underway to shape priorities for the “Next Big Thing” in the Center for … Read More
Managing the Challenges of Paying for Gene Therapy: New ICER / NEWDIGS whitepaper
ICER and NEWDIGS Release White Paper Analyzing the Challenges and Potential Policy Options for Paying for Gene Therapies — Paper outlines policy reforms and market actions to support innovation and … Read More
Better Outcomes Tracking: A First Step In Improving Access To New Treatments
New article in Health Affairs Forefront Transformative new pharmaceutical treatments hold the promise of changing patients’ lives by slowing and curing disease, improving well-being, and advancing quality of life. Yet, … Read More
NEWDIGS welcomes Dr. Sharon Phares as new Associate Director for Research
NEWDIGS at Tufts Medical Center is excited to announce that Sharon Phares, PhD, MPH, has joined the team as our Associate Director for Research, Center for Biomedical System Design (CBSD), Tufts Medicine earlier this … Read More
Orphan cell and gene therapies more likely to reach approval than larger drug pipeline: study
Our new report shows that cell and gene therapies for orphan diseases and hematological cancers are two to 3.5 times more likely to be successful than other types of treatments … Read More
New Analysis by Tufts’ NEWDIGS Shows that Durable Cell and Gene Therapies Have Substantially Higher Clinical Success Rates than Other Treatments
Findings to be shared during ARM’s annual Cell & Gene Meeting on the Mesa Carlsbad, CA – The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization championing the benefits … Read More